? Developmental Research Program The goal of the Developmental Research Program (DRP) in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant interventions that will reduce the burden of ovarian cancer. This program was highly successful over the last 5 years, with support going to 30 pilot projects, twelve of which have received additional funding outside of the SPORE based on their pilot project, two that were awarded a second year of funding, one that advanced to a full project within the first funding period, and six that provided data instrumental for the selection of the major research projects in this renewal. This relatively junior program, having received only 58 months of funding at the time of this writing, has 37 associated publications and 10 associated clinical trials. We will build on the success of our first funding period, which attracted investigators new to ovarian cancer research who ultimately became Principal Investigators of projects included in this SPORE application or were awarded NIH funding outside of the SPORE. The DRP will 1) foster innovative laboratory, population, and clinical study proposals that have strong translational potential; 2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The DRP will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support at least four meritorious projects with $50,000 to be used within one year. In the first five years of our SPORE, we generated $990K direct dollars of institutional/Foundation support, approximately double the $500K proposed in the application for this time period; we will continue to seek additional support for ovarian cancer research in the years to come. Depending on the progress of a given project, there will be the possibility of a second year of support after competitive review of both new and continuation projects. The DRP will utilize a defined process to call for applications on an annual basis and to review submissions, utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translational potential, qualifications of the key personnel, and interactivity. As experienced in our first funding period, it is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in existing SPORE-sponsored projects or through peer-reviewed external grant support.

Public Health Relevance

The Developmental Research Program supports young investigators or those new to ovarian cancer research, with the goal of identifying promising pilot studies. The objective of these preliminary studies is to generate new ideas that could be tested in larger projects or in clinical trials for ovarian cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-09
Application #
9540825
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
9
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Zhang, Qing; Wang, Chen; Cliby, William A (2018) Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol :
Morehead, Lauren C; Cannon, Martin J (2018) Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp 2:
Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Earp, Madalene; Tyrer, Jonathan P; Winham, Stacey J et al. (2018) Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 13:e0197561
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869

Showing the most recent 10 out of 294 publications